Dose Interruption/Reduction of TKIs in the First 3 Months of CML Treatment


Dose Interruption/Reduction of TKIs in the First 3 Months of CML Treatment
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Jorge E Cortes, MD (1/24/14) and Hagop M Kantarjian, MD (1/29/14)
Apperley JF et al. Dose interruption/reduction of tyrosine kinase inhibitors in the first 3 months of treatment of CML is associated with inferior early molecular responses and predicts for an increased likelihood of discontinuation of the 1st line agent. Proc ASH 2013;Abstract 93.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.